Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15937046 | 0.89 | POLB (0.55) | HPGDPOLBMEN1KMT2ACYP19A1 | |
| SCHEMBL15936869 | 0.82 | CYP19A1 (0.63) | POLBCYP19A1GAASMN1; SMN2CYP1A2 | |
| Acetic Acid SCHEMBL28342240 | 0.79 | CYP19A1 (0.62) | HPGDPOLBMEN1KMT2ACYP19A1 | |
| SCHEMBL17283083 | 0.78 | PFKFB3 (0.58) | HPGDPOLBMEN1KMT2ACYP19A1 | |
| SCHEMBL435010 | 0.76 | KDM4E (0.54) | HPGDPOLBKMT2AGAALMNA | |
| SCHEMBL17283076 | 0.75 | HPGD (0.57) | HPGDMEN1KMT2ACYP19A1GAA | |
| SCHEMBL4143003 | 0.74 | HPGD (0.69) | HPGDMEN1KMT2ACYP19A1GAA | |
| SCHEMBL795210 | 0.73 | HPGD (0.68) | HPGDPOLBMEN1KMT2ACYP19A1 | |
| SCHEMBL15242982 | 0.73 | HPGD (0.55) | HPGDPOLBMEN1KMT2ACYP19A1 | |
| SCHEMBL17283072 | 0.73 | CYP19A1 (0.70) | HPGDMEN1KMT2ACYP19A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
| US-20170231956-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-08-17 | — | — | US | disclosed |
| US-9708335-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Apytinyx Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9579304-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Aptinyx, Inc. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160368926-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Incorporated (US) | 2016-12-22 | — | — | US | disclosed |
| US-9512134-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Aptinyx, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9504670-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Aptinyx, Inc. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160289240-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2016-10-06 | — | — | US | disclosed |
| US-20160122359-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2016-05-05 | — | — | US | disclosed |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289240-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HPGD 699/4885POLB 4447/4885MEN1 2012/4885 |
| US-20160368926-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HPGD 699/4885POLB 4447/4885MEN1 2012/4885 |
| US-20170231956-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HPGD 699/4885POLB 4447/4885MEN1 2012/4885 |
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HPGD 699/4885POLB 4447/4885MEN1 2012/4885 |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HPGD 699/4885POLB 4447/4885MEN1 2012/4885 |
| US-20160122359-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | HPGD 1515/4885POLB 4186/4885MEN1 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.